Entera Bio Ltd (ENTX) - Total Assets
Based on the latest financial reports, Entera Bio Ltd (ENTX) holds total assets worth $17.41 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Entera Bio Ltd to assess how comfortably operating cash covers total debt obligations.
Entera Bio Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Entera Bio Ltd for net asset value and shareholders' equity analysis.
Entera Bio Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Entera Bio Ltd's total assets of $17.41 Million consist of 95.6% current assets and 4.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.2% |
| Accounts Receivable | $126.00K | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Entera Bio Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ENTX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Entera Bio Ltd's current assets represent 95.6% of total assets in 2024, an increase from 69.2% in 2015.
- Cash Position: Cash and equivalents constituted 92.2% of total assets in 2024, up from 43.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Entera Bio Ltd Competitors by Total Assets
Key competitors of Entera Bio Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Entera Bio Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.83 | 6.61 | 4.95 |
| Quick Ratio | 10.83 | 6.61 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.44 Million | $6.23 Million | $7.27 Million |
Entera Bio Ltd - Advanced Valuation Insights
This section examines the relationship between Entera Bio Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.53 |
| Latest Market Cap to Assets Ratio | 6.84 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | $9.39 Million |
| Market Capitalization | $64.20 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Entera Bio Ltd's assets at a significant premium (6.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Entera Bio Ltd's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Entera Bio Ltd (2015–2024)
The table below shows the annual total assets of Entera Bio Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $9.39 Million | -20.19% |
| 2023-12-31 | $11.77 Million | -10.38% |
| 2022-12-31 | $13.13 Million | -49.49% |
| 2021-12-31 | $25.99 Million | +167.30% |
| 2020-12-31 | $9.72 Million | -41.79% |
| 2019-12-31 | $16.70 Million | +25.20% |
| 2018-12-31 | $13.34 Million | +0.47% |
| 2017-12-31 | $13.28 Million | +111.23% |
| 2016-12-31 | $6.29 Million | +128.83% |
| 2015-12-31 | $2.75 Million | -- |
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more